VSIR and neoplasm: Since VISTA protein may also be expressed on the tumour cells in various human neoplasms, where it correlates with an acquired resistance to anti-PD-1 immunotherapy and poor patient survival, co-blockade therapy against PD-L1 and VISTA has been proposed.